Overview Financials News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
ARGENX SE (ARGX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/05/2023 |
6-K
| Quarterly results |
05/05/2022 |
6-K
| Quarterly results |
10/22/2020 |
6-K
| Quarterly results |
05/14/2020 |
6-K
| Quarterly results |
10/24/2019 |
6-K
| Quarterly results |
05/09/2019 |
6-K
| Quarterly results |
10/25/2018 |
6-K
| Quarterly results |
05/09/2018 |
6-K
| Quarterly results
Docs:
|
"6-K",
"argenx announces results of Annual General Meeting of Shareholders",
"Voting Results from the Annual General Meeting of Shareholders held on May 8, 2018",
"argenx reports first quarter 2018 financial results and provides business update Breda, the Netherlands / Ghent, Belgium — argenx , a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the first quarter ended March 31, 2018. “We made excellent progress this quarter in executing on our pipeline strategy and are well-prepared for another milestone-rich year ahead in 2018. To start with our lead program efgartigimod , we presented the full data set from the Phase 2 clinical trial in myasthenia gravis at the American Academy of Neurology Annual Meeting showing a reduction in disease scores that correlated with o..." |
|
10/26/2017 |
6-K
| Quarterly results |
|
|